J Vet Res. 2019 Sep 13;63(3):399-403. doi: 10.2478/jvetres-2019-0051. eCollection 2019 Sep.
Effect of Selected Nonsteroidal Anti-inflammatory Drugs on the Viability of Canine Osteosarcoma Cells of the D-17 Line: .
Journal of veterinary research
Dominik Poradowski, Bożena Obmińska-Mrukowicz
Affiliations
Affiliations
- Division of Animal Anatomy, Department of Biostructure and Animal Physiology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 51-631 Wroc?aw, Poland.
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 50-375 Wroc?aw, Poland.
PMID: 31572821
PMCID: PMC6749731 DOI: 10.2478/jvetres-2019-0051
Abstract
INTRODUCTION: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in veterinary medicine. They are used in pain control and in anti-inflammatory and antipyretic therapies. Some NSAIDs,
MATERIAL AND METHODS: The viability of the cells was evaluated using the MTT assay. Four independent repetitions were performed and the results are given as the average of these values; EC
RESULTS: The analysis of results showed that carprofen and tolfenamic acid displayed the highest cytotoxicity. Other drugs either did not provide such effects or they were very poor. For carprofen, it was possible to determine an EC
CONCLUSION: The results are promising but further studies should be conducted to confirm them, since this study is only preliminary. The possibility of introducing carprofen and tolfenamic acid into the routine treatment of osteosarcoma in dogs should be considered.
© 2019 D. Poradowski, B. Obmińska-Mrukowicz. published by Sciendo.
Keywords: canine osteosarcoma; cytotoxicity assay; dogs; non-steroidal anti-inflammatory drugs
Conflict of interest statement
Conflict of Interest Conflict of Interests Statement: The authors declare that there is no conflict of interests regarding the publication of this article.
References
- J Vet Pharmacol Ther. 2007 Dec;30(6):503-7 - PubMed
- J Natl Cancer Inst. 2006 Jun 21;98(12):855-68 - PubMed
- J Am Vet Med Assoc. 1992 Apr 1;200(7):995-9 - PubMed
- J Am Vet Med Assoc. 2007 Oct 1;231(7):1076-80 - PubMed
- Urology. 2008 Jan;71(1):156-60 - PubMed
- J Vet Intern Med. 2004 Nov-Dec;18(6):859-65 - PubMed
- Int J Cancer. 2001 Mar 15;91(6):894-9 - PubMed
- Mol Carcinog. 2013 May;52(5):377-86 - PubMed
- J Am Vet Med Assoc. 2005 Apr 15;226(8):1364-7 - PubMed
- Urology. 2005 Dec;66(6):1239-44 - PubMed
- J Vet Intern Med. 2012 Jul-Aug;26(4):977-86 - PubMed
- BMC Vet Res. 2014 Sep 05;10:184 - PubMed
- Mol Cancer Ther. 2008 Nov;7(11):3539-45 - PubMed
- Eur J Pharmacol. 1994 Mar 3;253(3):191-200 - PubMed
- J Small Anim Pract. 1996 Aug;37(8):371-5 - PubMed
- Invest New Drugs. 2011 Feb;29(1):41-51 - PubMed
- Gynecol Oncol. 2011 Jul;122(1):163-70 - PubMed
- Cancer Sci. 2011 Apr;102(4):742-8 - PubMed
- Carcinogenesis. 2009 Jul;30(7):1193-201 - PubMed
- Vet J. 1998 Jul;156(1):31-9 - PubMed
Publication Types